Browse online courses created through SITC’s collaborative partnerships.

Collaborative Partnership Courses
Collapse Case Studies in Lung Cancer: Test Your Skills

Access Course

 

Enhance your clinical skills as you engage with patients in an objective and realistic interactive simulation. Treat patients, diagnose medical conditions, and prescribe medications. There are no limits to your choices—order from thousands of labs, diagnoses, devices, and drugs using an intuitive patient chart-based interface. Powerful metrics track your performance and provide instant expert feedback on your decisions. Upon completion, results will be presented, along with author commentary on each case.

 

This activity is intended for hematologist/oncologist specialists.

 

The goal of this activity is to provide clinicians with the latest data, concepts, and recommendations regarding the diagnosis, biomarker testing, evidence-based frontline treatment, and potential treatment-related adverse events of patients with advanced lung cancer.

 

Learning Objectives:

  • Select appropriate diagnostic and biomarker tests to guide treatment selection for a patient with advanced lung cancer.
  • Order an appropriate, evidence-based frontline treatment regimen for a patient with advanced lung cancer.
  • Provide patient education for potential treatment-related adverse events.

 

Approximate Time to Complete: 30 minutes

 

Credit Available: Mar. 18, 2020 - Mar. 18, 2021

 

Developed through a partnership between SITC and Medscape.

sitc_log_color.png     

Medscape_EDU-RGB-2x-300.png

 

Additional Lung Cancer Resources for Clinicans from SITC:

 

sitc-cig-rgb.png"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)" (Published July 17, 2018)

 

 

View Guidelines Here.

View On-demand Webinar Here.

Original Course Date: March 19, 2020

Approved Credit:
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Case Studies in Lung Cancer: Test Your Skills
    Collapse Spotlight on the Future of Treatment Algorithms in Melanoma: Where Are We Headed?

    Access Course

     

    Spotlight on the Future of Treatment Algorithms in Melanoma: Where Are We Headed?Experts discuss the use of checkpoint inhibition in metastatic melanoma as well as its expansion into the adjuvant setting and beyond.

     

    This activity is intended for oncologists, dermatologists, and other healthcare professionals who treat patients with melanoma.

     

    The goal of this activity is to increase understanding of the latest advances in the use of immunotherapy for the treatment of melanoma.

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Mar. 4, 2020 - Mar. 4, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

    Original Course Date: March 04, 2020

    Approved Credit:
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Spotlight on the Future of Treatment Algorithms in Melanoma: Where Are We Headed?
    Collapse Expert Insights on Emerging Data for the Use of Immunotherapy in Advanced RCC

    Access Course

     

    Expert Insights on Emerging Data for the Use of Immunotherapy in Advanced RCCWatch experts discuss the latest data in immunotherapy as well as strategies for managing patients with advanced RCC.

     

    This activity is intended for oncologists, urologists, nephrologists, nurses and nurse practitioners, pharmacists, and other healthcare providers who manage patients with renal cell carcinoma (RCC).

     

    The goal of this activity is to increase understanding of the latest advances in the use of checkpoint inhibition in patients with advanced RCC.

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Jan. 30, 2020 - Jan. 30, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

    Original Course Date: January 30, 2020

    Approved Credit:
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ANCC: 0.50 hours Contact Hour
  • ACPE: 0.05 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Expert Insights on Emerging Data for the Use of Immunotherapy in Advanced RCC
    Collapse Updates in the Role of Immune Checkpoint Inhibitors for the Management of RCC

    Access Course

     

    Updates in the Role of Immune Checkpoint Inhibitors for the Management of RCCDrs Pal and Hammers discuss data and clinical pearls for the use of checkpoint inhibitors in RCC.

     

    This activity is intended for hematologists/oncologists and urologists.

     

    The goal of this activity is to improve knowledge and competence related to the role of immune checkpoint inhibitors (ICIs) as monotherapy and combination therapy for patients with renal cell carcinoma (RCC).

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Jan. 21, 2020 - Jan. 21, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

    Original Course Date: January 21, 2020

    Approved Credit:
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Updates in the Role of Immune Checkpoint Inhibitors for the Management of RCC
    Collapse Novel Insights Into the Use of Immune Checkpoint Inhibitors in Lung Cancer

    Access Course

     

    Immune Checkpoint Inhibitors in Lung Cancer: No Longer the Road Less Traveled?Experts discuss emerging clinical trial data on the use of immune checkpoint inhibitors in the management of advanced lung cancers.

     

     

    This activity is intended for hematologists/oncologists, pulmonologists, pathologists, nurses, and pharmacists.

     

     

    The goal of this activity is to improve knowledge regarding recent clinical trial data on the use of immune checkpoint inhibitors (ICIs) alone or in combination in advanced lung cancers.

     

     

     

    Approximate Time to Complete: 45 minutes

     

    Credit Available: Dec. 26, 2019 - Dec. 26, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

    Original Course Date: December 26, 2019

    Approved Credit:
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 0.08 hours CEU
  • ANCC: 0.75 hours Contact Hour

  • MORE INFOMORE INFO Novel Insights Into the Use of Immune Checkpoint Inhibitors in Lung Cancer
    Collapse Going Beyond PD-(L)1 Inhibition: Where Can Manipulating the Immune System take Cancer Care?

    Access Course

     

    Immune Checkpoint Inhibitors in Lung Cancer: No Longer the Road Less Traveled?Learn about agents that target pathways in solid tumors other than PD-1/PD-L1

     

    This activity is intended for hematologists/oncologists, nurses, and pharmacists.

     

    The goal of this activity is to improve knowledge regarding immunotherapy pathways beyond programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1), and data for agents that target these pathways.

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Dec. 26, 2019 - Dec. 26, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

    Original Course Date: December 26, 2019

    Approved Credit:
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 0.05 hours CEU
  • ANCC: 0.50 hours Contact Hour

  • MORE INFOMORE INFO Going Beyond PD-(L)1 Inhibition: Where Can Manipulating the Immune System take Cancer Care?
    Collapse Optimizing Outcomes in Melanoma: A Case Challenge

    Access Course

     

    Immune Checkpoint Inhibitors in Lung Cancer: No Longer the Road Less Traveled?Apply best practices to the diagnosis and management of patients with melanoma.

     

    This activity is intended for hem/onc specialists, dermatologists, emergency medicine physicians, and nurse practitioners.

     

    The goal of this activity is to provide clinicians with the latest data, concepts, and recommendations regarding the work-up, treatment, and follow-up of patients with melanoma.

     

    Approximate Time to Complete: 60 minutes

     

    Credit Available: Dec. 13, 2019 - Dec. 13, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

    Original Course Date: December 13, 2019

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ANCC: 1 hour Contact Hour

  • MORE INFOMORE INFO Optimizing Outcomes in Melanoma: A Case Challenge
    Collapse The Nurse View: What Do You Need to Know About Immune Checkpoint Inhibitors

    Access Course

     

    The Nurse View: What Do You Need to Know About Immune Checkpoint Inhibitors?Experts discuss pressing issues related to checkpoint inhibitor use, including irAEs and use in autoimmune disease and organ transplant.

     

    This activity is intended for nurses, nurse practitioners, and other healthcare professionals who treat cancer patients with immune checkpoint inhibitors.

     

    The goal of this activity is to increase understanding of the issues surrounding immune checkpoint inhibitors (ICIs), including the risk for immune-related adverse events (irAEs) and optimal patient/caregiver communication.

     

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Nov. 25, 2019 - Nov. 25, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 27, 2019

    Approved Credit:
  • ANCC: 0.50 hours Contact Hour

  • MORE INFOMORE INFO The Nurse View: What Do You Need to Know About Immune Checkpoint Inhibitors
    Collapse Opportunities and Possibilities: Cancer Immunotherapy in the Management of GI Cancers

    Access Course

     

    Opportunities and Possibilities: Cancer Immunotherapy in the Management of GI Cancers

    The latest advances in immunotherapy for CRC, HCC, and gastroesophageal cancers are explored in these 3 columns.

     

     

    This activity is intended for oncologists, gastroenterologists, and other healthcare professionals who treat patients with gastrointestinal (GI) cancers.

     

     

    The goal of this activity is to increase understanding of the advances and challenges of using checkpoint inhibitors in the treatment of patients with GI cancers.

     

     

     

    Approximate Time to Complete: 1 hour

     

    Credit Available: November 27, 2019 - November 27, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 27, 2019

    Approved Credit:
  • ACCME: 1 hour AMA PRA Category 1 Credit(s)
  • ABIM: 1 hour ABIM MOC Part 2 Credits

  • MORE INFOMORE INFO Opportunities and Possibilities: Cancer Immunotherapy in the Management of GI Cancers
    Collapse Best Practices in the Management of SCCHN With Checkpoint Inhibition

    Access Course

     

    Best Practices in the Management of SCCHN With Checkpoint InhibitionDr Dan Zandberg reviews the latest understanding in the use of checkpoint inhibition in SCCHN through an examination of 3 cases.

     

    This activity is intended for oncologists, surgeons, and pathologists.

     

    The goal of this activity is to increase understanding of the use of checkpoint inhibition in advanced squamous cell carcinoma of the head and neck (SCCHN) as well as ongoing research into its use earlier in the disease setting.

     

     

     

    Approximate Time to Complete: 1 hour

     

    Credit Available: May 9, 2019 - May 9, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: May 09, 2019

    Approved Credit:
  • ACCME: 1 hour AMA PRA Category 1 Credit(s)
  • ABIM: 1 hour ABIM MOC Part 2 Credits

  • MORE INFOMORE INFO Best Practices in the Management of SCCHN With Checkpoint Inhibition
    Collapse Patient-Centered Care in Advanced Bladder Cancer

    Access Course

     

    Patient-Centered Care in Advanced Bladder CancerExperts discuss the evolving role of checkpoint inhibition in patients with advanced bladder cancer.

    This activity is intended for oncologists, urologists, and other healthcare professionals who treat patients with bladder cancer.

    The goal of this activity is to discuss the role of immunotherapy, including how to determine eligibility and how to manage immune-related adverse events (irAEs), in the treatment of advanced bladder cancer.

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Apr. 30, 2019- Apr. 30, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: April 30, 2019

    Approved Credit:
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Patient-Centered Care in Advanced Bladder Cancer
    Collapse The Nurse View: Modulating the Immune System in GI Cancers

    Access Course

     

    The Nurse View: Modulating the Immune System in GI CancersNursing experts discuss the emergence of immunotherapy in GI cancers, focusing on the role of biomarkers and the management of irAEs.

     

    This activity is intended for nurses and other healthcare professionals who manage patients with gastrointestinal cancers.

     

    The goal of this activity is to discuss the emerging role of immunotherapy using immune checkpoint inhibitors in patients with gastrointestinal cancers.

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Apr. 30, 2019 - Apr. 30, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: April 30, 2019

    Approved Credit:
  • ANCC: 0.50 hours Contact Hour

  • MORE INFOMORE INFO The Nurse View: Modulating the Immune System in GI Cancers
    Collapse Management of Advanced Bladder Cancer: What You Should Know

    Access Course

     

    This article is for people who have advanced bladder cancer or anyone who wants to learn more about advanced bladder cancer. The goal of this patient education activity is to make patients more aware of available treatment options for advanced bladder cancer.

     

     

     

     

     

    You will learn about:

     

    • What chemotherapy is and how it is used to treat advanced bladder cancer
    • What checkpoint inhibitors are and how they are used to treat advanced bladder cancer
    • The potential side effects of chemotherapy and checkpoint inhibitors
    • Why the side effects from chemotherapy and checkpoint inhibitors are different
    • Questions to ask your doctor

     

    Available beginning: April 26, 2019

     

    Approximate Time to Complete: 30 minutes

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: April 26, 2019
    MORE INFOMORE INFO Management of Advanced Bladder Cancer: What You Should Know
    Collapse Going Beyond EXTREME in Head and Neck Cancer

    Access Course

     

    Going Beyond EXTREME in Head and Neck CancerExperts discuss the emergence of checkpoint inhibition in the first-line treatment of SCCHN as well as its ongoing role in second-line treatment.

     

     

    This activity is intended for oncologists, surgeons, and pathologists.

     

     

    The goal of this activity is to discuss the evolving role of immunotherapy in patients with squamous cell carcinoma of the head and neck (SCCHN).

     

     

    Approximate Time to Complete: 30 minutes

     

     

    Credit Available: Mar. 26, 2019 - Mar. 26, 2020

     

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: March 26, 2019

    Approved Credit:
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits

  • MORE INFOMORE INFO Going Beyond EXTREME in Head and Neck Cancer
    Collapse Moving Care Forward in Advanced Gastric Cancer: What, When, and in Whom

    Access Course

     

    Moving Care Forward in Advanced Gastric Cancer: What, When,and in WhomExperts discuss the emerging research into the use of checkpoint inhibitors in gastric and GE junction cancers

     

    This activity is intended for oncologists, gastroenterologists, nurses, and other healthcare professionals who manage patients with gastric cancer.

     

    The goal of this activity is to discuss the emerging role of immunotherapy in patients with gastric and gastroesophageal junction cancers.

     

     

    Approximate Time to Complete: 45 minutes

     

     

    Credit Available: Mar. 26, 2019 - Mar. 26, 2020

     

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: March 26, 2019

    Approved Credit:
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits

  • MORE INFOMORE INFO Moving Care Forward in Advanced Gastric Cancer: What, When, and in Whom
    Collapse Melanoma: Steps to Optimizing Clinical Outcomes

    Access Course

    Explore the latest in melanoma care through 2 cases, one in the adjuvant setting and one in the metastatic setting.

     

    This activity is intended for oncologists, dermatologists, pathologists, nurses, pharmacists, and other healthcare professionals who manage patients with melanoma.

     

     

     

     

    Credit Available: Feb. 25, 2019 - Feb. 25, 2020

     

    Approximate Time to Complete: 75 minutes

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: February 25, 2019
    MORE INFOMORE INFO Melanoma: Steps to Optimizing Clinical Outcomes